Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation.
about
Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantationThe distinct clinical features and prognosis of the CD10⁺MUM1⁺ and CD10⁻Bcl6⁻MUM1⁻ diffuse large B-cell lymphoma.CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium PrAllogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantationDiffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy.The role of autologous stem cell transplantation in the treatment of diffuse large B-cell lymphoma.A bio-clinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma.Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma.Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma.Outcome of R-CHOP or CHOP regimen for germinal center and nongerminal center subtypes of diffuse large B-cell lymphoma of Chinese patients
P2860
Q34325329-F1DD1317-67F8-44A2-AA8B-9B866ECF4BA7Q36559885-A82C1CB0-0B41-48C4-BAE2-65FA18E2A9EBQ36979534-3F0A78DC-1207-446D-8021-B810CACADFF4Q37006876-DF3FBDDD-7E5F-4FDC-9FAE-64C7871573E9Q37083601-EB8010F0-3BA4-41E9-984D-FDC84EF24DF7Q38138170-42E010C5-F887-4BFE-B4B1-CDA69FD117A1Q38376595-06C72092-1225-47F4-BF10-6B5823D56193Q40144297-3DB69227-EB53-4422-8B3B-BDE623346BDFQ40795258-25B83DF0-15AD-442F-9B71-731D753E7213Q47447676-80387365-B9CE-41BB-AA21-43F87FF4AA98Q48222205-D65A24C4-59C0-427F-85FE-3941ABD9DC24Q53089847-1F4B82FF-C818-4A4B-A240-D286989239ABQ58915114-A43CCF17-4AB8-42DA-A733-5EF77B95B40F
P2860
Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Cell of origin fails to predic ...... tic stem cell transplantation.
@ast
Cell of origin fails to predic ...... tic stem cell transplantation.
@en
type
label
Cell of origin fails to predic ...... tic stem cell transplantation.
@ast
Cell of origin fails to predic ...... tic stem cell transplantation.
@en
prefLabel
Cell of origin fails to predic ...... tic stem cell transplantation.
@ast
Cell of origin fails to predic ...... tic stem cell transplantation.
@en
P2093
P2860
P50
P356
P1476
Cell of origin fails to predic ...... tic stem cell transplantation.
@en
P2093
Lynette M Smith
Martin Bast
Patricia Aoun
Philip J Bierman
R Gregory Bociek
Timothy C Greiner
Zhongfen Liu
P2860
P304
P356
10.1002/HON.1017
P577
2011-10-18T00:00:00Z